Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Options GDR Silver Project, Silvertip-Midway District, Yukon (click to learn more) Ciscom Corp. Strengthens Its Board of Directors with Addition of Two Experienced Industry Leaders (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gamida Cell Ltd GMDAQ

Healthcare Biotechnology
Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and... see more

Recent & Breaking News (OTCPK:GMDAQ)

Gamida Cell to Report Second Quarter 2023 Financial Results

Business Wire August 1, 2023

Data Published in Transplantation and Cellular Therapy Suggest Antiviral Protection After Transplantation with Gamida Cell's Omisirge® (omidubicel-onlv)

Business Wire July 11, 2023

STAND UP TO CANCER NAMES JULIAN ADAMS, Ph.D., CHIEF SCIENCE OFFICER

PR Newswire July 10, 2023

Gamida Cell To Host Investor Day

Business Wire June 14, 2023

Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference

Business Wire May 31, 2023

Data To Be Presented on Gamida Cell Natural Killer (NK) Cell Therapy Candidate GDA-201 at the International Society for Cell & Gene Therapy 2023 Annual Meeting

Business Wire May 31, 2023

Gamida Cell Reports First Quarter 2023 Financial Results and Provides Company Update

Business Wire May 15, 2023

Gamida Cell Announces the Date of Its First Quarter 2023 Financial Results and Webcast

Business Wire May 11, 2023

Gamida Cell Announces Pricing of $23 Million Public Offering of Securities

Business Wire April 19, 2023

Gamida Cell Announces Launch of Public Offering of Securities

Business Wire April 18, 2023

Gamida Cell's Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval

Business Wire April 17, 2023

Gamida Cell Reports Full Year 2022 Financial Results and Provides Company Update

Business Wire March 27, 2023

Gamida Cell Announces Changes to Board of Directors

Business Wire March 20, 2023

Gamida Cell Announces the Date of Its Fourth Quarter and Full Year 2022 Financial Results and Webcast

Business Wire March 20, 2023

Gamida Cell to Present Corporate Highlights at the Oppenheimer 33rd Annual Healthcare Conference

Business Wire March 7, 2023

Data Presented on Gamida Cell's Omidubicel, GDA-201 at the 2023 Tandem Meetings of ASTCT and CIBMTR

Business Wire February 18, 2023

Gamida Cell Announces Closing of $25 Million Financing With Highbridge

Business Wire December 12, 2022

Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences

Business Wire November 23, 2022

Gamida Cell Provides Regulatory Update on Omidubicel

Business Wire November 21, 2022

Gamida Cell Reports Third Quarter 2022 Financial Results and Provides Company Update

Business Wire November 14, 2022